Literature DB >> 28500192

Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.

Barbara Farrell1, Kevin Pottie2, Wade Thompson3, Taline Boghossian4, Lisa Pizzola5, Farah Joy Rashid4, Carlos Rojas-Fernandez6, Kate Walsh7, Vivian Welch8, Paul Moayyedi9.   

Abstract

OBJECTIVE: To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes.
METHODS: Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process included the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, with a detailed evidence review in in-person, telephone, and online meetings. Uniquely, the guideline development process included a systematic review of PPI deprescribing trials and examination of reviews of the harm of continued PPI use. Narrative syntheses of patient preferences and resource-implication literature informed recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and then to health care professional associations for review and revisions made at each stage. A decision-support algorithm was developed in conjunction with the guideline. RECOMMENDATIONS: This guideline recommends deprescribing PPIs (reducing dose, stopping, or using "on-demand" dosing) in adults who have completed a minimum of 4 weeks of PPI treatment for heartburn or mild to moderate gastroesophageal reflux disease or esophagitis, and whose symptoms are resolved. The recommendations do not apply to those who have or have had Barrett esophagus, severe esophagitis grade C or D, or documented history of bleeding gastrointestinal ulcers.
CONCLUSION: This guideline provides practical recommendations for making decisions about when and how to reduce the dose of or stop PPIs. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28500192      PMCID: PMC5429051     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  51 in total

1.  Overutilization of proton-pump inhibitors: what the clinician needs to know.

Authors:  Joel J Heidelbaugh; Andrea H Kim; Robert Chang; Paul C Walker
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

2.  Concordance between use of proton pump inhibitors and prescribing guidelines.

Authors:  P I Pillans; P A Kubler; J M Radford; V Overland
Journal:  Med J Aust       Date:  2000-01-03       Impact factor: 7.738

Review 3.  A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Authors:  Gwen M C Masclee; Miriam C J M Sturkenboom; Ernst J Kuipers
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

4.  Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial.

Authors:  A W van der Velden; N J de Wit; A O Quartero; D E Grobbee; M E Numans
Journal:  Digestion       Date:  2009-12-22       Impact factor: 3.216

Review 5.  The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis.

Authors:  Paul Moayyedi; Brendan C Delaney; Nimish Vakil; David Forman; Nicholas J Talley
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Qualitative insights into general practitioners views on polypharmacy.

Authors:  Sibyl Anthierens; Anneleen Tansens; Mirko Petrovic; Thierry Christiaens
Journal:  BMC Fam Pract       Date:  2010-09-15       Impact factor: 2.497

7.  Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.

Authors:  A L Gough; R G Long; B T Cooper; C S Fosters; A D Garrett; C H Langworthy
Journal:  Aliment Pharmacol Ther       Date:  1996-08       Impact factor: 8.171

8.  Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.

Authors:  M Robinson; F Lanza; D Avner; M Haber
Journal:  Ann Intern Med       Date:  1996-05-15       Impact factor: 25.391

9.  Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise.

Authors:  Holger J Schünemann; Wojtek Wiercioch; Itziar Etxeandia; Maicon Falavigna; Nancy Santesso; Reem Mustafa; Matthew Ventresca; Romina Brignardello-Petersen; Kaja-Triin Laisaar; Sérgio Kowalski; Tejan Baldeh; Yuan Zhang; Ulla Raid; Ignacio Neumann; Susan L Norris; Judith Thornton; Robin Harbour; Shaun Treweek; Gordon Guyatt; Pablo Alonso-Coello; Marge Reinap; Jan Brozek; Andrew Oxman; Elie A Akl
Journal:  CMAJ       Date:  2013-12-16       Impact factor: 8.262

Review 10.  Deprescribing versus continuation of chronic proton pump inhibitor use in adults.

Authors:  Taline A Boghossian; Farah Joy Rashid; Wade Thompson; Vivian Welch; Paul Moayyedi; Carlos Rojas-Fernandez; Kevin Pottie; Barbara Farrell
Journal:  Cochrane Database Syst Rev       Date:  2017-03-16
View more
  92 in total

1.  Problem-based deprescribing: Using your patients' clinical concerns to guide medication review.

Authors:  Frank Molnar; Chris Frank
Journal:  Can Fam Physician       Date:  2019-04       Impact factor: 3.275

2.  Approach to GERD.

Authors:  Val E Ginzburg
Journal:  Can Fam Physician       Date:  2017-08       Impact factor: 3.275

3. 

Authors:  Peter J Zed
Journal:  Can J Hosp Pharm       Date:  2018-10-31

4.  Deprescribing Proton Pump Inhibitors.

Authors:  Peter J Zed
Journal:  Can J Hosp Pharm       Date:  2018-10-31

5.  Only full adherence to proton pump inhibitors protects against drug-induced upper gastrointestinal bleeding.

Authors:  Borja Ruiz; Urko Aguirre; Ana Estany-Gestal; Luca Rodella; Pablo Ruiz; Adolfo Figueiras; Alfonso Carvajal; Luisa Ibáñez; Anita Conforti; Marian M de Pancorbo; Xavier Vidal; Luis H Martin; Carmelo Aguirre
Journal:  Eur J Clin Pharmacol       Date:  2018-07-24       Impact factor: 2.953

6.  Associations Between Polypharmacy, Symptom Burden, and Quality of Life in Patients with Advanced, Life-Limiting Illness.

Authors:  Yael Schenker; Seo Young Park; Kwonho Jeong; Jennifer Pruskowski; Dio Kavalieratos; Judith Resick; Amy Abernethy; Jean S Kutner
Journal:  J Gen Intern Med       Date:  2019-02-04       Impact factor: 5.128

7.  The hidden curriculum and continuing professional development for family physicians.

Authors:  Nicholas Pimlott
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

8.  The French Society of Internal Medicine's Top-5 List of Recommendations: a National Web-Based Survey.

Authors:  Nathan Peiffer-Smadja; Adeline Bauvois; Marie Chilles; Baptiste Gramont; Redwan Maatoug; Marie Bismut; Camille Thorey; Eric Oziol; Thomas Hanslik
Journal:  J Gen Intern Med       Date:  2019-06-12       Impact factor: 5.128

Review 9.  Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem.

Authors:  Takeshi Kanno; Paul Moayyedi
Journal:  Curr Gastroenterol Rep       Date:  2019-12-05

10.  The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.

Authors:  Manvi Sharma; Holly M Holmes; Hemalkumar B Mehta; Hua Chen; Rajender R Aparasu; Ya-Chen T Shih; Sharon H Giordano; Michael L Johnson
Journal:  Cancer       Date:  2019-01-03       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.